Targeting angiogenesis with compounds from the extracellular matrix

International Journal of Biochemistry and Cell Biology

Volumn 43, Issue 12, 2011, Pages 1674-1685

  Belotti, Dorina ^a   Foglieni, Chiara ^a   Resovi, Andrea ^a   Giavazzi, Raffaella ^a   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Extracellular matrix; Inhibitors of angiogenesis; Mimetic small molecules; Peptides; Proteolytic fragments

Indexed keywords

ABT 898; ANASTELLIN; ANGIOGENESIS INHIBITOR; CILENGITIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 15; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CVX 045; ENDOREPELLIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JSM 6472; L 000845704; METICRANE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLATELET DERIVED GROWTH FACTOR; PTX 008; RECOMBINANT PROTEIN; RESTIN; S 36578; SB 273005; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; EXTRACELLULAR MATRIX; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 80255123709     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2011.08.012     Document Type: Review

References (152)

1. J.C. Adams, and R.P. Tucker The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development Dev Dyn 218 2000 280 299 (Pubitemid 30349640)
2. J.C. Adams Functions of the conserved thrombospondin carboxy-terminal cassette in cell-extracellular matrix interactions and signaling Int J Biochem Cell Biol 36 2004 1102 1114 (Pubitemid 38501562)
3. J.C. Adams, and J. Lawler The thrombospondins Int J Biochem Cell Biol 36 2004 961 968 (Pubitemid 38528716)
4. A. Akalu, J.M. Roth, M. Caunt, D. Policarpio, L. Liebes, and P.C. Brooks Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin Cancer Res 67 2007 4353 4363 (Pubitemid 46815084)
5. G. Allegrini, A. Falcone, A. Fioravanti, M.T. Barletta, P. Orlandi, and F. Loupakis A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br J Cancer 98 2008 1312 1319 (Pubitemid 351543577)
6. J.L. Andres, K. Stanley, S. Cheifetz, and J. Massague Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta J Cell Biol 109 1989 3137 3145 (Pubitemid 20011937)
7. C.J. Avraamides, B. Garmy-Susini, and J.A. Varner Integrins in angiogenesis and lymphangiogenesis Nat Rev Cancer 8 2008 604 617
8. A. Beenken, and M. Mohammadi The FGF family: biology, pathophysiology and therapy Nat Rev Drug Discov 8 2009 235 253
9. A.J. Beer, H. Kessler, H.J. Wester, and M. Schwaiger PET imaging of integrin alphaVbeta3 expression Theranostics 1 2011 48 57
10. D. Belotti, P. Paganoni, L. Manenti, A. Garofalo, S. Marchini, and G. Taraboletti Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation Cancer Res 63 2003 5224 5229 (Pubitemid 37139832)
11. D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, and R. Giavazzi Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion Mol Cancer Res 6 2008 525 534 (Pubitemid 351521834)
12. G. Bergers, R. Brekken, G. McMahon, T.H. Vu, T. Itoh, and K. Tamaki Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat Cell Biol 2 2000 737 744
13. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410 (Pubitemid 37328844)
14. G. Bix, and R.V. Iozzo Matrix revolutions: "tails" of basement-membrane components with angiostatic functions Trends Cell Biol 15 2005 52 60 (Pubitemid 40094681)
15. G. Bocci, G. Francia, S. Man, J. Lawler, and R.S. Kerbel Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proc Natl Acad Sci USA 100 2003 12917 12922 (Pubitemid 37340000)
16. K. Bonezzi, R. Frapolli, F. Sala, L. Astorgues-Xerri, M. Serova, and E. Raymon PTX-008, a dual inhibitor of angiogenesis and tumor cell proliferation, potentiates the antineoplastic activity of targeted therapies in human tumor models Annual Meeting of the American Association for Cancer Research 2011 AACR Orlando, Florida Nr 3289
17. P. Bornstein Thrombospondins as matricellular modulators of cell function J Clin Invest 107 2001 929 934 (Pubitemid 32323400)
18. C. Bossard, L. Van den Berghe, H. Laurell, C. Castano, M. Cerutti, and A.C. Prats Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide Cancer Res 64 2004 7507 7512 (Pubitemid 39372095)
19. E. Chautard, M. Fatoux-Ardore, L. Ballut, N. Thierry-Mieg, and S. Ricard-Blum MatrixDB, the extracellular matrix interaction database Nucleic Acids Res 39 2010 D235 D240
20. X. Chen, Y. Su, B. Fingleton, H. Acuff, L.M. Matrisian, and R. Zent Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells Int J Cancer 116 2005 52 61 (Pubitemid 40827754)
21. M.E. Cianfrocca, K.A. Kimmel, J. Gallo, T. Cardoso, M.M. Brown, and G. Hudes Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours Br J Cancer 94 2006 1621 1626 (Pubitemid 43924924)
22. G. Colombo, B. Margosio, L. Ragona, M. Neves, S. Bonifacio, and D.S. Annis Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds J Biol Chem 285 2010 8733 8742
23. A. Corti, F. Curnis, W. Arap, and R. Pasqualini The neovasculature homing motif NGR: more than meets the eye Blood 112 2008 2628 2635
24. A.M. Cuesta, D. Sanchez-Martin, L. Sanz, J. Bonet, M. Compte, and L. Kremer In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences PLoS One 4 2009 e5381
25. G.E. Davis, K.J. Bayless, M.J. Davis, and G.A. Meininger Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules Am J Pathol 156 2000 1489 1498 (Pubitemid 30646688)
26. D.W. Dawson, O.V. Volpert, S.F. Pearce, A.J. Schneider, R.L. Silverstein, and J. Henkin Three distinct d-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat Mol Pharmacol 55 1999 332 338 (Pubitemid 29076031)
27. R.A. Dean, G.S. Butler, Y. Hamma-Kourbali, J. Delbe, D.R. Brigstock, and J. Courty Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis Mol Cell Biol 27 2007 8454 8465
28. M. Degen, F. Brellier, R. Kain, C. Ruiz, L. Terracciano, and G. Orend Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior Cancer Res 67 2007 9169 9179 (Pubitemid 47535903)
29. M. Dews, A. Homayouni, D. Yu, D. Murphy, C. Sevignani, and E. Wentzel Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster Nat Genet 38 2006 1060 1065 (Pubitemid 44325933)
30. S.P. Dineen, L.A. Sullivan, A.W. Beck, A.F. Miller, J.G. Carbon, and R. Mamluk The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer BMC Cancer 8 2008 352
31. R.P. Dings, D.W. van der Schaft, B. Hargittai, J. Haseman, A.W. Griffioen, and K.H. Mayo Anti-tumor activity of the novel angiogenesis inhibitor anginex Cancer Lett 194 2003 55 66 (Pubitemid 36428885)
32. R.P. Dings, X. Chen, D.M. Hellebrekers, L.I. van Eijk, Y. Zhang, and T.R. Hoye Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities J Natl Cancer Inst 98 2006 932 936 (Pubitemid 44018923)
33. R.P. Dings, E.S. Van Laar, J. Webber, Y. Zhang, R.J. Griffin, and S.J. Waters Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven Cancer Lett 265 2008 270 280
34. G. Dorman, S. Cseh, I. Hajdu, L. Barna, D. Konya, and K. Kupai Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility Drugs 70 2010 949 964
35. S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti, and M. Cordenonsi Role of YAP/TAZ in mechanotransduction Nature 474 2011 179 183
36. C. Faye, E. Chautard, B.R. Olsen, and S. Ricard-Blum The first draft of the endostatin interaction network J Biol Chem 284 2009 22041 22047
37. A.L. Feldman, W.G. Stetler-Stevenson, N.G. Costouros, V. Knezevic, G. Baibakov, and H.R. Alexander Jr. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism Cancer Res 64 2004 4481 4486 (Pubitemid 38856919)
38. I.S. Fernandez, P. Cuevas, J. Angulo, P. Lopez-Navajas, A. Canales-Mayordomo, and R. Gonzalez-Corrochano Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors J Biol Chem 285 2010 11714 11729
39. N. Ferrara Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action Mol Biol Cell 21 2010 687 690
40. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286 (Pubitemid 46505878)
41. Y. Fu, H. Tang, Y. Huang, N. Song, and Y. Luo Unraveling the mysteries of endostatin IUBMB Life 61 2009 613 626
42. S.A. Garside, J. Henkin, K.D. Morris, S.M. Norvell, F.H. Thomas, and H.M. Fraser A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo Endocrinology 151 2010 5905 5915
43. A. Gautam, C.L. Densmore, S. Melton, E. Golunski, and J.C. Waldrep Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis Cancer Gene Ther 9 2002 28 36 (Pubitemid 34052851)
44. E.R. Gerstner, A.F. Eichler, S.R. Plotkin, J. Drappatz, C.L. Doyle, and L. Xu Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide J Neurooncol 2010
45. S. Goldoni, and R.V. Iozzo Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs Int J Cancer 123 2008 2473 2479
46. D.J. Good, P.J. Polverini, F. Rastinejad, M.M. Le Beau, R.S. Lemons, and W.A. Frazier A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin Proc Natl Acad Sci USA 87 1990 6624 6628
47. A. Goyal, N. Pal, M. Concannon, M. Paul, M. Doran, and C. Poluzzi Endorepellin, perlecan angiostatic module, interacts with both the [alpha]2[beta]1 integrin and VEGFreceptor 2: a dual receptor antagonism J Biol Chem 2011
48. A.W. Griffioen, D.W. van der Schaft, A.F. Barendsz-Janson, A. Cox, H.A. Struijker Boudier, and H.F. Hillen Anginex, a designed peptide that inhibits angiogenesis Biochem J 354 2001 233 242 (Pubitemid 32209858)
49. Y. Hamano, H. Sugimoto, M.A. Soubasakos, M. Kieran, B.R. Olsen, and J. Lawler Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression Cancer Res 64 2004 1570 1574 (Pubitemid 38428672)
50. H.K. Hamilton, A.E. Rose, P.J. Christos, R.L. Shapiro, R.S. Berman, and M. Mazumdar Increased shedding of HU177 correlates with worse prognosis in primary melanoma J Transl Med 8 2010 19
51. R. Haubner, A.J. Beer, H. Wang, and X. Chen Positron emission tomography tracers for imaging angiogenesis Eur J Nucl Med Mol Imaging 37 Suppl. 1 2010 S86 S103
52. F. Haviv, M.F. Bradley, D.M. Kalvin, A.J. Schneider, D.J. Davidson, and S.M. Majest Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities J Med Chem 48 2005 2838 2846 (Pubitemid 40548098)
53. R. Hoekstra, F.Y. de Vos, F.A. Eskens, J.A. Gietema, A. van der Gaast, and H.J. Groen Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer J Clin Oncol 23 2005 5188 5197 (Pubitemid 46224028)
54. K.A. Houck, D.W. Leung, A.M. Rowland, J. Winer, and N. Ferrara Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms J Biol Chem 267 1992 26031 26037 (Pubitemid 23014012)
55. R.O. Hynes Cell-matrix adhesion in vascular development J Thromb Haemost 5 Suppl. 1 2007 32 40 (Pubitemid 46964284)
56. R.O. Hynes The extracellular matrix: not just pretty fibrils Science 326 2009 1216 1219
57. D.E. Ingber Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology Circ Res 91 2002 877 887 (Pubitemid 35373587)
58. M.L. Iruela-Arispe, A. Luque, and N. Lee Thrombospondin modules and angiogenesis Int J Biochem Cell Biol 36 2004 1070 1078 (Pubitemid 38501558)
59. R.K. Jain, D.G. Duda, C.G. Willett, D.V. Sahani, A.X. Zhu, and J.S. Loeffler Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
60. Y. Jiang, M. Wang, M.Y. Celiker, Y.E. Liu, Q.X. Sang, and I.D. Goldberg Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery Cancer Res 61 2001 2365 2370 (Pubitemid 32685806)
61. Y. Jing, H. Lu, K. Wu, I.V. Subramanian, and S. Ramakrishnan Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins Int J Cancer 2011
62. R. Kalluri Basement membranes: structure, assembly and role in tumour angiogenesis Nat Rev Cancer 3 2003 422 433 (Pubitemid 37328846)
63. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, and D.A. Lacorre Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 2009 2542 2552
64. E.D. Karagiannis, and A.S. Popel Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties Biochem Biophys Res Commun 354 2007 434 439 (Pubitemid 46161343)
65. E.D. Karagiannis, and A.S. Popel A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells Proc Natl Acad Sci USA 105 2008 13775 13780
66. B. Kaur, D.J. Brat, N.S. Devi, and E.G. Van Meir Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor Oncogene 24 2005 3632 3642 (Pubitemid 40756232)
67. S.H. Kim, J. Turnbull, and S. Guimond Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor J Endocrinol 209 2011 139 151
68. J.E. Koskimaki, E.D. Karagiannis, B.C. Tang, H. Hammers, D.N. Watkins, and R. Pili Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model BMC Cancer 10 2010 29
69. A. Kuehbacher, C. Urbich, A.M. Zeiher, and S. Dimmeler Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis Circ Res 101 2007 59 68 (Pubitemid 47094624)
70. N.V. Lee, M. Sato, D.S. Annis, J.A. Loo, L. Wu, and D.F. Mosher ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2 EMBO J 25 2006 5270 5283 (Pubitemid 44764137)
71. S. Lee, S.M. Jilani, G.V. Nikolova, D. Carpizo, and M.L. Iruela-Arispe Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors J Cell Biol 169 2005 681 691 (Pubitemid 41002860)
72. T.Y. Lee, R.M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E.A. Pravda, and K.M. Lo Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy Clin Cancer Res 14 2008 1487 1493 (Pubitemid 351413933)
73. T.Y. Lee, J. Folkman, and K. Javaherian HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model PLoS One 5 2010 e9945
74. N.J. Levin, T.A. Leedom, V.R. Doppalapudi, L. Li, J. Lai, and K. Johnson CVX-045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body that potentiates chemotherapy in preclinical colon cancer models J Clin Oncol 25 2007 14011
75. X. Li, Y.H. Liu, S.J. Lee, T.A. Gardner, M.H. Jeng, and C. Kao Prostate-restricted replicative adenovirus expressing human endostatin- angiostatin fusion gene exhibiting dramatic antitumor efficacy Clin Cancer Res 14 2008 291 299 (Pubitemid 351378005)
76. D. Lipovsek Adnectins: engineered target-binding protein therapeutics Protein Eng Des Sel 24 2011 3 9
77. R. Mamluk, I.M. Carvajal, B.A. Morse, H. Wong, J. Abramowitz, and S. Aslanian Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2 MAbs 2 2010
78. B. Margosio, D. Marchetti, V. Vergani, R. Giavazzi, M. Rusnati, and M. Presta Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2 Blood 102 2003 4399 4406 (Pubitemid 37494101)
79. B. Margosio, M. Rusnati, K. Bonezzi, B.L. Cordes, D.S. Annis, and C. Urbinati Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain Int J Biochem Cell Biol 40 2008 700 709 (Pubitemid 351288589)
80. E. Martina, M. Degen, C. Ruegg, A. Merlo, M.M. Lino, and R. Chiquet-Ehrismann Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro FASEB J 24 2010 778 787
81. M.M. Martino, and J.A. Hubbell The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain FASEB J 24 2010 4711 4721
82. C. Mas-Moruno, F. Rechenmacher, and H. Kessler Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anticancer Agents Med Chem 10 2010 753 768
83. S. Maubant, D. Saint-Dizier, M. Boutillon, F. Perron-Sierra, P.J. Casara, and J.A. Hickman Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells Blood 108 2006 3035 3044
84. D.S. Mendelson, M. Dinolfa, R.B. Cohen, L.S. Rosen, M.S. Gordon, and B. Byrnes First-in-human dose escalation safety and pharmacokynetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors J Clin Oncol 26 2008 3524
85. M. Millard, S. Odde, and N. Neamati Integrin targeted therapeutics Theranostics 1 2011 154 188
86. M. Mongiat, S.M. Sweeney, J.D. San Antonio, J. Fu, and R.V. Iozzo Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan J Biol Chem 278 2003 4238 4249 (Pubitemid 36801161)
87. J. Mueller, F.C. Gaertner, B. Blechert, K.P. Janssen, and M. Essler Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo Mol Cancer Res 7 2009 1078 1085
88. T.M. Mundel, and R. Kalluri Type IV collagen-derived angiogenesis inhibitors Microvasc Res 74 2007 85 89 (Pubitemid 350051026)
89. T.M. Mundel, A.M. Yliniemi, Y. Maeshima, H. Sugimoto, M. Kieran, and R. Kalluri Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth Int J Cancer 122 2008 1738 1744 (Pubitemid 351413419)
90. K.A. Myers, K.T. Applegate, G. Danuser, R.S. Fischer, and C.M. Waterman Distinct ECM mechanosensing pathways regulate microtubule dynamics to control endothelial cell branching morphogenesis J Cell Biol 192 2011 321 334
91. D. Neri, and R. Bicknell Tumour vascular targeting Nat Rev Cancer 5 2005 436 446 (Pubitemid 40791486)
92. B. Ng, J. Zakrzewski, M. Warycha, P.J. Christos, D.F. Bajorin, and R.L. Shapiro Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients Clin Cancer Res 14 2008 6253 6258
93. G. Niu, and X. Chen Why integrin as a primary target for imaging and therapy Theranostics 1 2011 30 47
94. P. Nyberg, L. Xie, and R. Kalluri Endogenous inhibitors of angiogenesis Cancer Res 65 2005 3967 3979 (Pubitemid 40775631)
95. M.S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, and W.S. Lane Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285 (Pubitemid 28015876)
96. A. Ori, M.C. Wilkinson, and D.G. Fernig A systems biology approach for the investigation of the heparin/heparan sulfate interactome J Biol Chem 286 2011 19892 19904
97. J.E. Park, G.A. Keller, and N. Ferrara The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1993 1317 1326 (Pubitemid 24045761)
98. A. Prudova, U. auf dem Keller, G.S. Butler, and C.M. Overall Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics Mol Cell Proteomics 9 2010 894 911
99. J.H. Qi, Q. Ebrahem, N. Moore, G. Murphy, L. Claesson-Welsh, and M. Bond A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 Nat Med 9 2003 407 415 (Pubitemid 36460074)
100. A.J. Quesada, T. Nelius, R. Yap, T.A. Zaichuk, A. Alfranca, and S. Filleur In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment Cell Death Differ 12 2005 649 658 (Pubitemid 40767167)
101. E.W. Raines, and R. Ross Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences J Cell Biol 116 1992 533 543
102. R. Ramchandran, M. Dhanabal, R. Volk, M.J. Waterman, M. Segal, and H. Lu Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin Biochem Biophys Res Commun 255 1999 735 739 (Pubitemid 29294868)
103. D.A. Reardon, L.B. Nabors, R. Stupp, and T. Mikkelsen Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme Expert Opin Investig Drugs 17 2008 1225 1235
104. F.K. Reiher, O.V. Volpert, B. Jimenez, S.E. Crawford, C.P. Dinney, and J. Henkin Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics Int J Cancer 98 2002 682 689 (Pubitemid 34225618)
105. A.R. Reynolds, I.R. Hart, A.R. Watson, J.C. Welti, R.G. Silva, and S.D. Robinson Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat Med 15 2009 392 400
106. S. Ricard-Blum, and L. Ballut Matricryptins derived from collagens and proteoglycans Front Biosci 16 2011 674 697
107. P. Richter, M. Tost, M. Franz, A. Altendorf-Hofmann, K. Junker, and L. Borsi B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 135 2009 1351 1358
108. F. Robert, M.S. Gordon, L.S. Rosen, D.S. Mendelson, M. Mulay, and B.J. Adams Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer J Clin Oncol 28 15s 2010 (suppl; abstr 3038)
109. S.M. Rudman, M.B. Jameson, M.J. McKeage, P. Savage, D.I. Jodrell, and M. Harries A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma Clin Cancer Res 17 2011 1998 2005
110. C. Ruegg, M. Hasmim, F.J. Lejeune, and G.C. Alghisi Antiangiogenic peptides and proteins: from experimental tools to clinical drugs Biochim Biophys Acta 1765 2006 155 177 (Pubitemid 44294394)
111. E. Ruoslahti, S.N. Bhatia, and M.J. Sailor Targeting of drugs and nanoparticles to tumors J Cell Biol 188 2010 759 768
112. M. Rusnati, P. Oreste, G. Zoppetti, and M. Presta Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery Curr Pharm Des 11 2005 2489 2499 (Pubitemid 40872693)
113. M. Rusnati, and M. Presta Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey Endothelium 13 2006 93 111 (Pubitemid 44173111)
114. M. Rusnati, C. Urbinati, S. Bonifacio, M. Presta, and G. Taraboletti Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action Pharmaceuticals 3 2010 1241 1278
115. A. Santoro, T. Pressiani, G. Citterio, G. Rossoni, G. Donadoni, and F. Pozzi Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma Br J Cancer 103 2010 837 844
116. T. Sasaki, H. Larsson, D. Tisi, L. Claesson-Welsh, E. Hohenester, and R. Timpl Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity J Mol Biol 301 2000 1179 1190
117. C. Schliemann, and D. Neri Antibody-based targeting of the tumor vasculature Biochim Biophys Acta 1776 2007 175 192 (Pubitemid 350061071)
118. M. Schuksz, M.M. Fuster, J.R. Brown, B.E. Crawford, D.P. Ditto, and R. Lawrence Surfen, a small molecule antagonist of heparan sulfate Proc Natl Acad Sci USA 105 2008 13075 13080
119. D.W. Seo, H. Li, L. Guedez, P.T. Wingfield, T. Diaz, and R. Salloum TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism Cell 114 2003 171 180 (Pubitemid 36936911)
120. R. Silva, G. D'Amico, K.M. Hodivala-Dilke, and L.E. Reynolds Integrins: the keys to unlocking angiogenesis Arterioscler Thromb Vasc Biol 28 2008 1703 1713
121. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, and M. Wang A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 2009 5296 5300
122. T.H. Stollman, T.J. Ruers, W.J. Oyen, and O.C. Boerman New targeted probes for radioimaging of angiogenesis Methods 48 2009 188 192
123. M. Streit, A.E. Stephen, T. Hawighorst, K. Matsuda, B. Lange-Asschenfeldt, and L.F. Brown Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy Cancer Res 62 2002 2004 2012 (Pubitemid 34408444)
124. Y. Suarez, C. Fernandez-Hernando, J. Yu, S.A. Gerber, K.D. Harrison, and J.S. Pober Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis Proc Natl Acad Sci USA 105 2008 14082 14087
125. I.V. Subramanian, R. Ghebre, and S. Ramakrishnan Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice Gene Ther 12 2005 30 38 (Pubitemid 40090042)
126. A. Sudhakar, and C.S. Boosani Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression Pharm Res 25 2008 2731 2739
127. F. Suhr, K. Brixius, and W. Bloch Angiogenic and vascular modulation by extracellular matrix cleavage products Curr Pharm Des 15 2009 389 410
128. K.N. Sulochana, H. Fan, S. Jois, V. Subramanian, F. Sun, and R.M. Kini Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis J Biol Chem 280 2005 27935 27948 (Pubitemid 41076911)
129. K.N. Sulochana, and R. Ge Developing antiangiogenic peptide drugs for angiogenesis-related diseases Curr Pharm Des 13 2007 2074 2086 (Pubitemid 47040489)
130. M. Sund, Y. Hamano, H. Sugimoto, A. Sudhakar, M. Soubasakos, and U. Yerramalla Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors Proc Natl Acad Sci USA 102 2005 2934 2939 (Pubitemid 40299894)
131. M. Sund, and R. Kalluri Tumor stroma derived biomarkers in cancer Cancer Metastasis Rev 28 2009 177 183
132. G. Taraboletti, D. Roberts, L.A. Liotta, and R. Giavazzi Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor J Cell Biol 111 1990 765 772
133. G. Taraboletti, A. Garofalo, D. Belotti, T. Drudis, P. Borsotti, and E. Scanziani Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases J Natl Cancer Inst 87 1995 293 298
134. G. Taraboletti, D. Belotti, P. Borsotti, V. Vergani, M. Rusnati, and M. Presta The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor Cell Growth Differ 8 1997 471 479 (Pubitemid 27273084)
135. G. Taraboletti, L. Morbidelli, S. Donnini, A. Parenti, H.J. Granger, and R. Giavazzi The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells FASEB J 14 2000 1674 1676
136. G. Taraboletti, and K. Bonezzi Inhibitors of angiogenesis based on thrombospondin-1 D. Ribatti, Recent advances in angiogenesis and antiangiogenesis 2009 Bentham Science Karachi, Pakistan 112 126
137. G. Taraboletti, M. Rusnati, L. Ragona, and G. Colombo Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors Oncotarget 1 2010 662 673
138. V.L. Thijssen, R. Postel, R.J. Brandwijk, R.P. Dings, I. Nesmelova, and S. Satijn Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy Proc Natl Acad Sci USA 103 2006 15975 15980 (Pubitemid 44657577)
139. A.W. Tolcher, C.J. Sweeney, K. Papadopoulos, A. Patnaik, E.G. Chiorean, and A.C. Mita Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin Clin Cancer Res 17 2011 363 371
140. J.R. Tysome, P. Wang, G. Alusi, A. Briat, R. Gangeswaran, and J. Wang Lister Vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer Hum Gene Ther 2011
141. N. Umeda, S. Kachi, H. Akiyama, G. Zahn, D. Vossmeyer, and R. Stragies Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist Mol Pharmacol 69 2006 1820 1828 (Pubitemid 43894298)
142. D.W. van der Schaft, R.P. Dings, Q.G. de Lussanet, L.I. van Eijk, A.W. Nap, and R.G. Beets-Tan The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models FASEB J 16 2002 1991 1993
143. I. Vlodavsky, J. Folkman, R. Sullivan, R. Fridman, R. Ishai-Michaeli, and J. Sasse Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix Proc Natl Acad Sci USA 84 1987 2292 2296 (Pubitemid 17075857)
144. M. Wang, Y.E. Liu, J. Greene, S. Sheng, A. Fuchs, and E.M. Rosen Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4 Oncogene 14 1997 2767 2774 (Pubitemid 27313408)
145. J. Xu, D. Rodriguez, E. Petitclerc, J.J. Kim, M. Hangai, and Y.S. Moon Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo J Cell Biol 154 2001 1069 1079 (Pubitemid 34286185)
146. R. Xu, Z.Y. Yao, L. Xin, Q. Zhang, T.P. Li, and R.B. Gan NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis Biochem Biophys Res Commun 289 2001 264 268 (Pubitemid 33108825)
147. Q. Yang, Y. Tian, S. Liu, R. Zeine, A. Chlenski, and H.R. Salwen Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma Cancer Res 67 2007 1716 1724 (Pubitemid 46383398)
148. R. Yap, D. Veliceasa, U. Emmenegger, R.S. Kerbel, L.M. McKay, and J. Henkin Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy Clin Cancer Res 11 2005 6678 6685 (Pubitemid 41339009)
149. M. Yi, and E. Ruoslahti A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis Proc Natl Acad Sci USA 98 2001 620 624 (Pubitemid 32105092)
150. X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin Clin Cancer Res 13 2007 3968 3976 (Pubitemid 47037605)
151. X. Zhou, R.G. Rowe, N. Hiraoka, J.P. George, D. Wirtz, and D.F. Mosher Fibronectin fibrillogenesis regulates three-dimensional neovessel formation Genes Dev 22 2008 1231 1243 (Pubitemid 351656581)
152. A.J. Zurita, E. Jonasch, X. Wang, M. Khajavi, S. Yan, and D.Z. Du A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma Ann Oncol 2011